This strategy produces a steady stream of income that exceeds what you can earn from bonds, with less risk. Read More

Merck has been a money-making machine for decades, but it faces growing competition and patent expirations. Will this drug giant prevail? Read More

Pfizer is a growth-and-income stock found in many retirement portfolios. But is the competition from biotech "disruptors" getting too hot for this Big Pharma stalwart? Read More

The last few years have been rough for biotech stocks, but Amgen has been a notable exception. It's now facing new threats from biosimilars. Can it continue to outperform? Read More